ACE inhibitors in vascular disease: some PROGRESS, more HOPE.
Lip
G Y
GY
University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. g.y.h.lip@bham.ac.uk
Beevers
D G
DG
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005544:Forecasting; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D020913:Perindopril / Q000008:administration & dosage*; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D020521:Stroke / Q000517:prevention & control*; D016896:Treatment Outcome; D006113:United Kingdom; D014652:Vascular Diseases / Q000175:diagnosis / Q000188:drug therapy*
D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril